AstraZeneca (LON:AZN) Given “Buy” Rating at Shore Capital

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Tuesday morning, Marketbeat.com reports.

A number of other equities analysts have also recently issued reports on the stock. BMO Capital Markets reissued an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. Berenberg Bank boosted their price target on shares of AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the stock a buy rating in a report on Friday, May 3rd. Jefferies Financial Group reissued a hold rating and issued a £110 ($139.81) target price on shares of AstraZeneca in a research report on Friday, February 16th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a hold rating and set a £105 ($133.45) price objective on shares of AstraZeneca in a research note on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of £118 ($149.97).

AstraZeneca Price Performance

AZN stock opened at £122.96 ($156.28) on Tuesday. The company’s fifty day simple moving average is £113.69 and its 200 day simple moving average is £106.82. AstraZeneca has a 12-month low of GBX 9,461 ($120.25) and a 12-month high of £124.88 ($158.72). The firm has a market cap of £190.59 billion, a price-to-earnings ratio of 3,842.50, a PEG ratio of 0.95 and a beta of 0.16. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.